ClinicalTrials.gg
RecruitingNCT06948656HYPOCIRUpdated Nov 20, 2026

Study of the Impact of HYPOglycaemia on Sarcopenia in CIRrhosis

An observational study in Cirrhosis, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 172 studies in Fibrosis with a site in France — 34 open to participants now, 39 under way, 4 of them phase 3. Fibrosis · France.

Planned enrollment
27th of 54
200 · median 200
Started
2025
with 13 others
Observational
54 of 172
15 open now
Primary completion
2027-10
later than 19 of 38 live
Registered
166th of 172
by date

Among the 172 studies in Fibrosis with a site in France, this one is the 27th largest by planned enrollment of the 54 observational ones that give a count, is one of 14 that started in 2025, is one of 54 observational ones, reaches primary completion later than 19 of the 38 other live ones, and was the 166th registered.

Fibrosis

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

Browse Fibrosis studies →

Open to participants now

34 of the 172 studies in Fibrosis with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 197 Fibrosis studies recruiting now, 112 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Fibrosis with a site in France, or all of them as a file.
02

Study summary

Fasting blood glucose is maintained by hepatic production of glucose from glycogenolysis or gluconeogenesis. In cirrhosis, glycogen storage capacity is reduced, with a consequent increase in gluconeogenesis to maintain blood glucose levels. Hypoglycaemia is particularly common during periods of prolonged nocturnal fasting. Cirrhosis can therefore be considered an 'accelerated fasting' disease. In a recent study, Honda et al. described 22% nocturnal hypoglycaemia in 105 patients analysed continuously. A previous study showed that the percentage of hypoglycaemia over the total duration of continuous blood glucose recording averaged 4%.

This gluconeogenesis could lead to a significant increase in muscle and fat catabolism, which would aggravate sarcopenia and lead to undernutrition. Undernutrition and sarcopenia are serious and severe in cirrhotic patients. Sarcopenia, present in around 45% to 67% of cirrhotic patients, is thought to lead to a significant increase in the morbidity and mortality of cirrhotic patients. Glycaemic disorders appear to play a major role in this sarcopenia. Shortening the duration of fasting, and therefore of proteolysis and lipolysis, by taking a snack in the evening, could improve nitrogen balance and glucose tolerance.

However, no study has clearly established the relationship between variations in continuous monitoring of interstitial glucose, particularly periods of nocturnal hypoglycaemia, and sarcopenia. New technologies in diabetology make it possible to obtain continuous monitoring of interstitial glucose. In addition, the use of muscle surface area at the level of the 3rd lumbar vertebra or the diameter of the psoas, obtained by scanner or MRI, combined with the use of a hand-held dynamometer to quantify muscle strength, make it easier to diagnose and assess the severity of sarcopenia and malnutrition.

The hypothesis of this work is based on the probable correlation between the time spent in hypoglycaemia (glycaemia \< 0.7 g/l) and the presence of sarcopenia responsible for undernutrition in cirrhotic patients.

If positive, the results of this descriptive pilot study could provide fundamental data for anticipating and better managing sarcopenia and glycaemic disorders. The results will enable a multi-centre randomised controlled intervention trial to be set up to optimise nutritional management of patients and thus effectively combat undernutrition in cirrhotic patients.

03

Conditions studied

  • Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cirrhotic subjects will be recruited from the hepato-gastroenterology departments of the centres taking part in this clinical study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Person with oral consent
  • Patient with cirrhosis according to the 2021 EASL criteria (1)
  • Patient receiving regular six-monthly and systematic monitoring of cirrhosis, according to the European recommendations of the EASL (2), or French recommendations of the TNCD (3) and HAS (4), including a clinical examination, a biological work-up (to calculate the score and monitor alpha-feto-protein), AND requiring imaging to screen for HCC of hepatocellular carcinoma using cross-sectional imaging (by MRI and/or hepatic CT scan).

Exclusion criteria

Exclusion Criteria:

  • Patients with active cancer or treated within the last 6 months
  • Patient with an acute episode of cirrhosis decompensation (ongoing antibiotic treatment for an active infection, gastrointestinal bleeding, hepatic encephalopathy, acute alcoholic hepatitis) less than one month old.
  • Treatment with systemic , in progress or within the last 3 months
  • Patient with organ transplant
  • Person not affiliated to or not benefiting from a social security scheme
  • Person under legal protection (curatorship, guardianship)
  • Person subject to a legal protection measure
  • Pregnant or breast-feeding women
  • An adult who is incapable or unable to give consent
  • Minors
  • Patients already included in an interventional study who may interfere with the evaluation of this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • patient

    Patients with cirrhosis according to the 2021 EASL criteria

    Other: fitting a blood glucose sensor · Other: food collection · Other: tests and questionnaires

Interventions

  • Otherfitting a blood glucose sensor

    automatic, continuous collection by the blood glucose sensor for 14 days

  • Otherfood collection

    14-day dietary record in a notebook for the patient

  • Othertests and questionnaires

    fragility test, measurement of muscle strength using a hand-held dynamometer, animal enumeration test, self-questionnaire on the frequency of consumption of the main food groups

06

What researchers measure

Primary outcomes

  1. The number of nocturnal dysglycaemic events by the blood glucose sensor

    Defined by an episode of hypoglycaemia (blood glucose \< 0.7 g/L), severe hypoglycaemia (blood glucose \< 0.55 g/L) or hyperglycaemia (blood glucose \> 1.8 g/L) lasting at least 15 consecutive minutes) of continuous recording of interstitial blood glucose (with Freestyle libre®). The nocturnal period is defined as the period between 11pm and 7am.

    Time frame: For 14 days

  2. Duration of nocturnal dysglycaemic events by the blood glucose sensor

    Defined by an episode of hypoglycaemia (blood glucose \< 0.7 g/L), severe hypoglycaemia (blood glucose \< 0.55 g/L) or hyperglycaemia (blood glucose \> 1.8 g/L) lasting at least 15 consecutive minutes) of continuous recording of interstitial blood glucose (with Freestyle libre®). The nocturnal period is defined as the period between 11pm and 7am.

    Time frame: For 14 days

  3. The severity of nocturnal dysglycaemic events by the blood glucose sensor

    Defined by an episode of hypoglycaemia (blood glucose \< 0.7 g/L), severe hypoglycaemia (blood glucose \< 0.55 g/L) or hyperglycaemia (blood glucose \> 1.8 g/L) lasting at least 15 consecutive minutes) of continuous recording of interstitial blood glucose (with Freestyle libre®). The nocturnal period is defined as the period between 11pm and 7am.

    Time frame: For 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.

Of 177 non-industry observational studies under Fibrosis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 105. This study's planned 25 months is below that.

Counting every sponsor, half of 186 studies reached it within 49 months; a quarter within 22 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
Apr 29, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and arm descriptions
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06948656
Responsible party
Sponsor
First posted
Apr 29, 2025
Start date
Sep 9, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Thomas MOUILLOT
Contact
Thomas.mouillot@chu-dijon.fr
0380293750 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion